Notably, additional islet-expressed class B1 GPCRs identified in our current analysis and other glycemic trait/T2D GWAS, including GIPR, GLP2R (refs. 3,66) and SCTR21, are investigational targets for T2D treatment, which should be subjected to similar analysis. This evidence concerns the gene GIPR and type 2 diabetes mellitus.